Abstract A40: Pancreatic cancer patient-derived orthotopic xenograft (PDOX™) is effectively targeted by Salmonella typhimurium A1-R

Abstract

Abstract The aim of this study is to determine the efficacy of tumor-targeting Salmonella typhimurium A1-R (A1-R) (Cancer Disc. 2, 588-590, 2012) on pancreatic cancer PDOX™ compared to standard chemotherapy. The PDOX™ was grown in transgenic nude red fluorescent protein (RFP) mice in order that the PDOX™ acquire RFP-expressing stroma in order to label the tumor. The RFP-PDOX™ were then orthotopically transplanted to non-transgenic nude mice in order to image tumor growth and drug efficacy. The RFP labeled stroma are stable upon passage. A1-R treatment significantly reduced tumor weight as well as tumor fluorescence area compared to untreated control (p = 0.011), with comparable efficacy of gemcitabine, cisplatin and 5-FU. A1-R had the highest efficacy compared to any of the chemotherapy drugs tested based on Evan's histological response criteria. The present report demonstrates Salmonella typhimurium A1-R was effective for human pancreatic PDOX™ and is a promising therapy for this highly treatment-resistant disease. Citation Format: Yukihiko Hiroshima, Ming Zhao, Ali Maawy, Yong Zhang, Matthew H.G. Katz, Jason B. Fleming, Fuminari Uehara, Shinji Miwa, Shuya Yano, Masashi Momiyama, Atsushi Suetsugu, Takashi Chishima, Kuniya Tanaka, Michael Bouvet, Itaru Endo, Robert M. Hoffman. Pancreatic cancer patient-derived orthotopic xenograft (PDOX™) is effectively targeted by Salmonella typhimurium A1-R. [abstract]. In: Proceedings of the AACR Special Conference: The Translational Impact of Model Organisms in Cancer; Nov 5-8, 2013; San Diego, CA. Philadelphia (PA): AACR; Mol Cancer Res 2014;12(11 Suppl):Abstract nr A40.